Luke M. Healy

The paper establishes a validated antibody platform for ALS research, identifying high-quality antibodies and revealing protein expression patterns in neurological cell types.

This study identifies the mTORC1-4E-BP1 axis as a neuroprotective mechanism in microglia under AD conditions, showing its role in suppressing inflammation and neurodegeneration.

The paper optimizes an iMGL protocol to generate microglia-like cells from an ALSP patient, revealing functional defects in migration and phagocytosis.

The paper shows TSPO expression increases in activated microglia in rodent models but not in human neurodegenerative diseases, indicating species-specific differences in TSPO function.

The paper compares culture media effects on human microglia, finding that serum supports key genes and phagocytic function, while CSF1R signaling reliance decreases in culture.

This study uses single-cell RNA sequencing to analyze spinal cord microglia responses to nerve injury, identifying sex- and time-specific changes and a role for ApoE in neuropathic pain.

The paper validates antibodies against the C9ORF72 protein, finding one specific monoclonal antibody and highlighting issues with others used in published studies.